Figure - available from: neurogenetics
This content is subject to copyright. Terms and conditions apply.
Illustration showing neurotransmitters synthesis, storage in vesicles, transport to presynaptic membrane upon membrane depolarization and Ca²⁺ release, then release of vesicle content into the synapse and re-uptake by specific transporters (SERT, DAT). Positive action of PKC phosphorylation increasing the recycling vesicle pool is also depicted. Tyrosine hydroxylase (TH) is the rate-limiting enzyme in catecholamine synthesis, catalyzing the conversion of tyrosine into 3,4-dihydroxy-phenylalanine (L-dopa). Catecholamines are synthesized in the nerves at the site of their release. TH requires BH4 and Fe⁺² as cofactors, and it is heavily modulated at both transcriptional and post-translational levels. It is inhibited by end products at two different levels. The first is a feedback mechanism on the enzyme activity that depends on the local concentration of catecholamines, and the second is the sequestration of the enzyme by long-term binding of the catalytic site to Fe⁺³ ions. The enzyme is heavily phosphorylated at four major N-terminal serine sites, which are the substrates for several protein kinases, including PKC. Phosphorylation of these serine residues results in enzyme activation, increase in enzyme activity or both [26]. Tryptophan hydroxylase (TPH) is the first enzyme in serotonin synthesis, converting tryptophan to 5-hydroxytryptophan. The level of tryptophan in the brain depends not only on blood levels but also on the levels of the other neutral amino acids, as they all share a common transporter through the blood–brain barrier [26]. Aromatic amino acid decarboxylase (AADC) catalyzes the conversion of L-dopa to dopamine. This enzyme also catalyzes the decarboxylation of 5-hydroxytryptophan to 5-hydroxytryptamine (serotonin). It is a pyridoxine-dependent enzyme. AADC is also heavily regulated at pre- and post-translational levels by receptors and protein kinases [26]. Biogenic amines are stored after synthesis in vesicles and are released by an exocytotic mechanism. Neurotransmitters are transported into vesicles by secondary transporters that use the H⁺ gradient established by a V-type H⁺-ATPase. There are three transport families in humans, named SLC17 (VGLUT, VNUT), SLC18 (VMAT), and SLC32 (VIAAT) [27]. Exocytosis is triggered by intracellular Ca⁺² and regulated by synaptotagmin via interaction with the SNARE/complexin complex. Other important proteins in vesicular exocytosis are synaptobrevin, syntaxin, synaptophysin, synaptogyrin, otoferlin, and SNAP25. These participate in the vesicle priming, docking, and opening of the synaptic vesicles and releasing their contents into the synaptic cleft [28]. Actin is a regulator of synaptic vesicle mobilization and exocytosis, and there are several regulators of cytoskeleton dynamics that act on proteins in the ADF/cofilin family. Actin is the most prominent cytoskeletal protein at synapses, being abundantly present in presynaptic terminals and postsynaptic dendritic spines [29]. Neurotransmitters activate cell-surface receptors that operate via distinct signaling mechanisms. These receptors include ligand-gated ion channels, receptors with intrinsic guanylyl cyclase activity, receptors with intrinsic or associated tyrosine kinase activity, or G-protein coupled receptors. The principal process for termination of monoaminergic neurotransmission is the uptake of dopamine and serotonin into the nerve terminals through the monoamine transporters DAT (dopamine transporter) and SERT (serotonin transporter). Monoamine transporters have functional regulation at different levels: long-term regulation at the gene level, short-term regulation through protein phosphorylation, and trafficking-dependent and trafficking-independent regulation (altered transporter surface expression). Abbreviations: P – phosphorylation, + activation, SERT – serotonin transporter, DAT – dopamine transporter, CaM – calmodulin, VMAT2 – vesicular monoamine transporter 2, PAH – phenylalanine hydroxylase, TH – tyrosine hydroxylase, AADC – aromatic L-amino acid decarboxylase, TPH – tryptophan hydroxylase, PKC – protein kinase C (original illustration by Vicky Earle)

Illustration showing neurotransmitters synthesis, storage in vesicles, transport to presynaptic membrane upon membrane depolarization and Ca²⁺ release, then release of vesicle content into the synapse and re-uptake by specific transporters (SERT, DAT). Positive action of PKC phosphorylation increasing the recycling vesicle pool is also depicted. Tyrosine hydroxylase (TH) is the rate-limiting enzyme in catecholamine synthesis, catalyzing the conversion of tyrosine into 3,4-dihydroxy-phenylalanine (L-dopa). Catecholamines are synthesized in the nerves at the site of their release. TH requires BH4 and Fe⁺² as cofactors, and it is heavily modulated at both transcriptional and post-translational levels. It is inhibited by end products at two different levels. The first is a feedback mechanism on the enzyme activity that depends on the local concentration of catecholamines, and the second is the sequestration of the enzyme by long-term binding of the catalytic site to Fe⁺³ ions. The enzyme is heavily phosphorylated at four major N-terminal serine sites, which are the substrates for several protein kinases, including PKC. Phosphorylation of these serine residues results in enzyme activation, increase in enzyme activity or both [26]. Tryptophan hydroxylase (TPH) is the first enzyme in serotonin synthesis, converting tryptophan to 5-hydroxytryptophan. The level of tryptophan in the brain depends not only on blood levels but also on the levels of the other neutral amino acids, as they all share a common transporter through the blood–brain barrier [26]. Aromatic amino acid decarboxylase (AADC) catalyzes the conversion of L-dopa to dopamine. This enzyme also catalyzes the decarboxylation of 5-hydroxytryptophan to 5-hydroxytryptamine (serotonin). It is a pyridoxine-dependent enzyme. AADC is also heavily regulated at pre- and post-translational levels by receptors and protein kinases [26]. Biogenic amines are stored after synthesis in vesicles and are released by an exocytotic mechanism. Neurotransmitters are transported into vesicles by secondary transporters that use the H⁺ gradient established by a V-type H⁺-ATPase. There are three transport families in humans, named SLC17 (VGLUT, VNUT), SLC18 (VMAT), and SLC32 (VIAAT) [27]. Exocytosis is triggered by intracellular Ca⁺² and regulated by synaptotagmin via interaction with the SNARE/complexin complex. Other important proteins in vesicular exocytosis are synaptobrevin, syntaxin, synaptophysin, synaptogyrin, otoferlin, and SNAP25. These participate in the vesicle priming, docking, and opening of the synaptic vesicles and releasing their contents into the synaptic cleft [28]. Actin is a regulator of synaptic vesicle mobilization and exocytosis, and there are several regulators of cytoskeleton dynamics that act on proteins in the ADF/cofilin family. Actin is the most prominent cytoskeletal protein at synapses, being abundantly present in presynaptic terminals and postsynaptic dendritic spines [29]. Neurotransmitters activate cell-surface receptors that operate via distinct signaling mechanisms. These receptors include ligand-gated ion channels, receptors with intrinsic guanylyl cyclase activity, receptors with intrinsic or associated tyrosine kinase activity, or G-protein coupled receptors. The principal process for termination of monoaminergic neurotransmission is the uptake of dopamine and serotonin into the nerve terminals through the monoamine transporters DAT (dopamine transporter) and SERT (serotonin transporter). Monoamine transporters have functional regulation at different levels: long-term regulation at the gene level, short-term regulation through protein phosphorylation, and trafficking-dependent and trafficking-independent regulation (altered transporter surface expression). Abbreviations: P – phosphorylation, + activation, SERT – serotonin transporter, DAT – dopamine transporter, CaM – calmodulin, VMAT2 – vesicular monoamine transporter 2, PAH – phenylalanine hydroxylase, TH – tyrosine hydroxylase, AADC – aromatic L-amino acid decarboxylase, TPH – tryptophan hydroxylase, PKC – protein kinase C (original illustration by Vicky Earle)

Source publication
Article
Full-text available
Monoamine neurotransmitter disorders present predominantly with neurologic features, including dystonic or dyskinetic cerebral palsy and movement disorders. Genetic conditions that lead to secondary defects in the synthesis, catabolism, transport, and metabolism of biogenic amines can lead to neurotransmitter abnormalities, which can present with s...

Similar publications

Article
Full-text available
Estrogen receptor-α (ERα) promotes breast cancer, and ER-positive cancer accounts for ~ 80% of breast cancers. This subtype responds positively to hormone/endocrine therapies involving either inhibition of estrogen synthesis or blockade of estrogen action. Carbidopa, a drug used to potentiate the therapeutic efficacy of L-DOPA in Parkinson's diseas...

Citations

... After initial screening, 134 articles were included for data extraction and analysis based on full-text review. [66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][112][113][114][115][116][117][118][119][120][121][122][123][124][125][126][127][128][129][130][131][132][133][134][135][136][137][138][139][140][141][142][143][144][145][146][147][148][149][150][151][152][153][154][155][156][157] These articles were most often case reports or cohort studies. ...
... These CAs and their metabolite levels in various disease conditions can be monitored for diagnosis of disease pathogenesis involving dopaminergic and adrenergic activity in disease state. [1,2] Over the past 20 years, these metabolites are diagnosed and detected in patients suffering from neuroendocrine tumors due to elevated levels of homovanillic acid (HVA), vanillylmandelic acid (VMA), and 5-hydroxyindoleacetic acid in urinary sample of patients. [3,4] On the other side, lower levels of these biogenic amine metabolites in healthy significant dopamine metabolite identified as a biotarget for PD, [6] L-4-hydroxy-3-methoxymandelic acid is an adrenaline and norepinephrine metabolite, while 5-hydroxyindole-3-acetic acid is a serotonin metabolite that is mostly excreted in the urine. ...
Article
Full-text available
Objective: The purpose of this study was to establish a validated analytical method for estimating the biogenic amine metabolites vanillylmandelic acid (VMA) and homovanillic acid (HVA) simultaneously using the high-performance liquid chromatography-ultraviolet (HPLC-UV) method. Materials and Methods: For the analysis of VMA and HVA in artificial urine samples, an HPLC method was devised and validated. The chromatographic separation was achieved on Kromasil C 8, 5 μm (125 mm × 4.6 mm) column at an ambient temperature of 25°C, with mobile phase combination of acetonitrile: 0.1% orthophosphoric acid in ratio of 30:70 v/v at a flow rate 0.5 mL/min using Agilent HPLC system. For the separation of these two metabolites, different mobile phases were used on a trial and error basis. In terms of linearity, accuracy, repeatability, precision, and robustness, the developed technique was validated according to ICH guidelines. Results: A high-resolution HPLC method was devised for the separation of VMA and HVA. VMA and HVA were found to be linear over the concentration range of 10 to 35 μg/mL, with coefficients of determination (r 2) of 0.955 and 0.963 for both metabolites, respectively. VMA and HVA had detection limits of 1.7 and 1.8 μg/mL, respectively, and quantification limits of 5.2 and 5.3 μg/mL. The results showed a low value of % relative standard deviation for repeatability, intra-and inter-day precision, and robustness studies. Conclusion: A validated HPLC-UV method was developed for estimating VMA and HVA in urine samples.